Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 9 (1), 133-139
- https://doi.org/10.1111/j.1538-7836.2010.04098.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.Clinical Pharmacokinetics, 2009
- Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modificationsThrombosis Research, 2008
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurrent Medical Research and Opinion, 2008
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 2008
- Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementThrombosis and Haemostasis, 2008
- Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1The Journal of Clinical Pharmacology, 2007
- Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.International journal of clinical pharmacology and therapeutics, 2007
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjectsEuropean Journal of Clinical Pharmacology, 2005
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorCancer Cell, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005